James Mark Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James Mark Jones has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Gordon W. Cran
2 shared publications- Mahmoud Loubani
Department of Cardiothoracic Surgery, Castle Hill Hospital, Cottingham HU16 5JQ, UK
2 shared publications A Kearney
Royal Victoria Hospital, Belfast, Northern Ireland
1 shared publicationAdam Ioannou
Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK
1 shared publication- Ahmed Torky
Department of Cardiology and Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool
1 shared publication - Aladdin Bashir
Cardiothoracic Surgery Department University Hospitals Plymouth NHS Trust Plymouth City UK
1 shared publication
Latest Publications
- Open Access
- 4 September 2023
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 94 (2)
Review of patients discharged post thoracic surgery with chest drain in situ and nurse-based follow-up clinic
Persistent air leak and prolonged drainage are recognized complications of thoracic surgery, increasing hospital stay and costs. Patients can be discharged with a chest drain and followed up in a nurse-led clinic. We reviewed such patients and the rate of readmission after discharge to assess the effectiveness of the drain follow up clinic. Retrospective review of our prospective database for 22 months (March 2019 to January 2021). Analysis focussed on indication and duration of chest drainage, complications, and readmission for any reason. 62 patients (representing 5% of all thoracic surgery patients) were discharged with a chest drain. Median age was 67 years (range 22-85 years), 24 females and 38 males. 52% underwent video-assisted thoracoscopic surgery, 27% had a thoracotomy, and 21% had bedside chest drain insertion. Following discharge, median duration of chest drainage was 11 days [interquartile range (IQR) 7-18.75 days]. Patients had 106 review episodes in the ward-based nurse-led clinic. Indication was prolonged air leak (71 %; 72 clinic reviews), persistent fluid drainage following empyema evacuation (16%; 24 clinic reviews) and persistent fluid drainage for simple effusion (13%; 10 clinic reviews). Median length of drain stay was 30 days (IQR 19.75-54 days) for empyema, 10 days (IQR 6-16 days) for air leak and 8 days (IQR 6.5-12 days) days for simple effusion. 9 patients required readmission (14.5%) and empyema had developed in 3 patients (4.8%). Patients discharged with a chest drain in place can be followed up in a dedicated ward-based nurse-led monitoring clinic for optimal quality of care.
- 4 September 2023
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 94 (2)
Open AccessReview of patients discharged post thoracic surgery with chest drain in situ and nurse-based follow-up clinic
Persistent air leak and prolonged drainage are recognized complications of thoracic surgery, increasing hospital stay and costs. Patients can be discharged with a chest drain and followed up in a nurse-led clinic. We reviewed such patients and the rate of readmission after discharge to assess the effectiveness of the drain follow up clinic. Retrospective review of our prospective database for 22 months (March 2019 to January 2021). Analysis focussed on indication and duration of chest drainage, complications, and readmission for any reason. 62 patients (representing 5% of all thoracic surgery patients) were discharged with a chest drain. Median age was 67 years (range 22-85 years), 24 females and 38 males. 52% underwent video-assisted thoracoscopic surgery, 27% had a thoracotomy, and 21% had bedside chest drain insertion. Following discharge, median duration of chest drainage was 11 days [interquartile range (IQR) 7-18.75 days]. Patients had 106 review episodes in the ward-based nurse-led clinic. Indication was prolonged air leak (71 %; 72 clinic reviews), persistent fluid drainage following empyema evacuation (16%; 24 clinic reviews) and persistent fluid drainage for simple effusion (13%; 10 clinic reviews). Median length of drain stay was 30 days (IQR 19.75-54 days) for empyema, 10 days (IQR 6-16 days) for air leak and 8 days (IQR 6.5-12 days) days for simple effusion. 9 patients required readmission (14.5%) and empyema had developed in 3 patients (4.8%). Patients discharged with a chest drain in place can be followed up in a dedicated ward-based nurse-led monitoring clinic for optimal quality of care.
- Open Access
- 19 April 2023
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 94 (1)
Redo aortic valve replacement vs valve-in-valve trans-catheter aortic valve implantation: a UK propensity-matched analysis
This study sought to compare the morbidity and mortality of redo aortic valve replacement (redo-AVR) versus valve-in-valve trans-catheter aortic valve implantation (valve-in-valve TAVI) for patients with a failing bioprosthetic valve. A multicentre UK retrospective study of redo-AVR or valve-in-valve TAVI for patients referred for redo aortic valve intervention due to a degenerated aortic bioprosthesis. Propensity score matching was performed for confounding factors. From July 2005 to April 2021, 911 patients underwent redo-AVR and 411 patients valve-in-valve TAVI. There were 125 pairs for analysis after propensity score matching. Mean age was 75.2±8.5 years. In-hospital mortality was 7.2% (n=9) for redo-AVR vs 0 for valve-in-valve TAVI, p=0.002. Surgical patients suffered more post-operative complications, including IABP support (p=0.02), early re-operation (p<0.001), arrhythmias (p<0.001), respiratory and neurological complications (p=0.02 and p=0.03) and multi-organ failure (p=0.01). The valve-in-valve TAVI group had a shorter intensive care unit and hospital stay (p <0.001 for both). However, moderate aortic regurgitation at discharge and higher post-procedural gradients were more common after valve-in-valve TAVI (p<0.001 for both). Survival probabilities in patients who were successfully discharged from hospital were similar after valve-in-valve TAVI and redo-AVR over the 6-year follow-up (log-rank p=0.26). In elderly patients with a degenerated aortic bioprosthesis, valve-in-valve trans-catheter aortic valve implantation provides better early outcomes, as opposed to redo surgical aortic valve replacement, although there was no difference in mid-term survival in patients successfully discharged from hospital.
- 19 April 2023
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 94 (1)
Open AccessRedo aortic valve replacement vs valve-in-valve trans-catheter aortic valve implantation: a UK propensity-matched analysis
This study sought to compare the morbidity and mortality of redo aortic valve replacement (redo-AVR) versus valve-in-valve trans-catheter aortic valve implantation (valve-in-valve TAVI) for patients with a failing bioprosthetic valve. A multicentre UK retrospective study of redo-AVR or valve-in-valve TAVI for patients referred for redo aortic valve intervention due to a degenerated aortic bioprosthesis. Propensity score matching was performed for confounding factors. From July 2005 to April 2021, 911 patients underwent redo-AVR and 411 patients valve-in-valve TAVI. There were 125 pairs for analysis after propensity score matching. Mean age was 75.2±8.5 years. In-hospital mortality was 7.2% (n=9) for redo-AVR vs 0 for valve-in-valve TAVI, p=0.002. Surgical patients suffered more post-operative complications, including IABP support (p=0.02), early re-operation (p<0.001), arrhythmias (p<0.001), respiratory and neurological complications (p=0.02 and p=0.03) and multi-organ failure (p=0.01). The valve-in-valve TAVI group had a shorter intensive care unit and hospital stay (p <0.001 for both). However, moderate aortic regurgitation at discharge and higher post-procedural gradients were more common after valve-in-valve TAVI (p<0.001 for both). Survival probabilities in patients who were successfully discharged from hospital were similar after valve-in-valve TAVI and redo-AVR over the 6-year follow-up (log-rank p=0.26). In elderly patients with a degenerated aortic bioprosthesis, valve-in-valve trans-catheter aortic valve implantation provides better early outcomes, as opposed to redo surgical aortic valve replacement, although there was no difference in mid-term survival in patients successfully discharged from hospital.
- Open Access
- 11 November 2021
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 34 (4) , 532-539
Cardiac surgery in older patients: hospital outcomes during a 15-year period from a complete national series
The objective was to review national trends in activity and hospital outcomes in older patients having cardiac surgery over a 15-year time period. Data were collected prospectively and uploaded to the National Institute for Cardiovascular Outcomes Research electronically. Data were validated, cleaned and processed using reproducible algorithms. Mortality was death in hospital after index operation. A total of 227 442 cardiac procedures were recorded in patients aged ≥70 years of which 46 354 were in those aged ≥80 years. Overall patients aged ≥70 years represented 43% of all adult cardiac surgery in the most recent study year. The annual proportion of surgery in patients ≥80 years increased from 4.1% to 10.8% between the first and last study years. There has been a significant linear increase in octogenarian valve [β 67.44, 95% confidence interval (CI) 55.04 to 79.83, P < 0.001] and coronary artery bypass graft surgery (β 32.53, 95% CI 6.16 to 58.90, P = 0.020) patients. In-hospital mortality reduced significantly for patients aged 70–79 years (β −0.17, 95% CI −0.20 to −0.13, P < 0.001) and all patients aged ≥80 (β −0.37, 95% CI −0.45 to −0.30, P < 0.001). The median length of hospital stay was 7 days for 70–79 and 9 days for ≥80 group, compared with 7 days for the whole cohort <70 years. This study represents the largest complete validated national dataset of cardiac surgery in the entire population of older patients. Octogenarians represent 11% of adult patients having cardiac surgery by the end of the study period, a three-fold increase from the start. In-hospital mortality in patients aged ≥80 years halved during study period to only 4% despite high logistic EuroSCORE of 15%. Cardiac surgery in octogenarians places a higher demand on resources, however, with an increased postoperative length of stay.
- 11 November 2021
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 34 (4) , 532-539
Open AccessCardiac surgery in older patients: hospital outcomes during a 15-year period from a complete national series
The objective was to review national trends in activity and hospital outcomes in older patients having cardiac surgery over a 15-year time period. Data were collected prospectively and uploaded to the National Institute for Cardiovascular Outcomes Research electronically. Data were validated, cleaned and processed using reproducible algorithms. Mortality was death in hospital after index operation. A total of 227 442 cardiac procedures were recorded in patients aged ≥70 years of which 46 354 were in those aged ≥80 years. Overall patients aged ≥70 years represented 43% of all adult cardiac surgery in the most recent study year. The annual proportion of surgery in patients ≥80 years increased from 4.1% to 10.8% between the first and last study years. There has been a significant linear increase in octogenarian valve [β 67.44, 95% confidence interval (CI) 55.04 to 79.83, P < 0.001] and coronary artery bypass graft surgery (β 32.53, 95% CI 6.16 to 58.90, P = 0.020) patients. In-hospital mortality reduced significantly for patients aged 70–79 years (β −0.17, 95% CI −0.20 to −0.13, P < 0.001) and all patients aged ≥80 (β −0.37, 95% CI −0.45 to −0.30, P < 0.001). The median length of hospital stay was 7 days for 70–79 and 9 days for ≥80 group, compared with 7 days for the whole cohort <70 years. This study represents the largest complete validated national dataset of cardiac surgery in the entire population of older patients. Octogenarians represent 11% of adult patients having cardiac surgery by the end of the study period, a three-fold increase from the start. In-hospital mortality in patients aged ≥80 years halved during study period to only 4% despite high logistic EuroSCORE of 15%. Cardiac surgery in octogenarians places a higher demand on resources, however, with an increased postoperative length of stay.
- Open Access
- 22 May 2020
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 189 (4) , 1289-1294
Permanent pacemaker implantation rates following cardiac surgery in the modern era
Aims: The aim of this study was to evaluate the incidence of permanent pacemaker (PPM) implantation after cardiac surgery in our institution and investigate risk factors for PPM dependency to provide patients with accurate incidence figures at the time of consent for surgery. Methods: Data was collected retrospectively from a single tertiary institution from October 2018 to April 2019 inclusive of 403 patients. Incidence of PPM implantation after various cardiac operations was evaluated. A univariate analysis was carried out to identify the independent risk factors related to PPM implantation. Results: Ten patients required a PPM (2.48%). The most common indication for PPM implantation post-cardiac surgery was complete heart block (N = 7, 70%) followed by bradycardia/pauses (N = 2, 20%) and sick sinus syndrome (N = 1, 10%). PPM implantation after coronary artery bypass graft (CABG) surgery was the lowest (0.63%), while combined CABG and valve operations had the highest incidence (5.97%). Independent risk predictors for PPM implantation included female gender (p = 0.03), rheumatic heart disease (p = 0.008), pulmonary hypertension (p = 0.01), redo operations (p = 0.002), mitral valve procedures (p = 0.001), tricuspid valve procedures (p = 0.0003) and combined mitral and tricuspid valve procedures (p = 0.0001). Average length of intensive care unit (ICU)/high-dependency unit (HDU) stay was significantly prolonged for patients who required a PPM post-cardiac surgery. Conclusion: As clinicians, it can be challenging to provide our patients with accurate information on the risk of PPM implantation relative to their operation. A unit-specific data may be a more accurate method of informing our patients on this risk.
- 22 May 2020
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 189 (4) , 1289-1294
Open AccessPermanent pacemaker implantation rates following cardiac surgery in the modern era
Aims: The aim of this study was to evaluate the incidence of permanent pacemaker (PPM) implantation after cardiac surgery in our institution and investigate risk factors for PPM dependency to provide patients with accurate incidence figures at the time of consent for surgery. Methods: Data was collected retrospectively from a single tertiary institution from October 2018 to April 2019 inclusive of 403 patients. Incidence of PPM implantation after various cardiac operations was evaluated. A univariate analysis was carried out to identify the independent risk factors related to PPM implantation. Results: Ten patients required a PPM (2.48%). The most common indication for PPM implantation post-cardiac surgery was complete heart block (N = 7, 70%) followed by bradycardia/pauses (N = 2, 20%) and sick sinus syndrome (N = 1, 10%). PPM implantation after coronary artery bypass graft (CABG) surgery was the lowest (0.63%), while combined CABG and valve operations had the highest incidence (5.97%). Independent risk predictors for PPM implantation included female gender (p = 0.03), rheumatic heart disease (p = 0.008), pulmonary hypertension (p = 0.01), redo operations (p = 0.002), mitral valve procedures (p = 0.001), tricuspid valve procedures (p = 0.0003) and combined mitral and tricuspid valve procedures (p = 0.0001). Average length of intensive care unit (ICU)/high-dependency unit (HDU) stay was significantly prolonged for patients who required a PPM post-cardiac surgery. Conclusion: As clinicians, it can be challenging to provide our patients with accurate information on the risk of PPM implantation relative to their operation. A unit-specific data may be a more accurate method of informing our patients on this risk.
49 Predictors and prognostic role of left ventricular ejection fraction recovery after st elevation myocardial infarction
Introduction Left ventricular ejection fraction (LVEF) is an important predictor of morbidity and mortality after ST elevation myocardial infarction (STEMI). In patients with left ventricular systolic dysfunction early after STEMI adverse ventricular remodelling can lead to a sustained reduction in LVEF, however, in some cases improvement may occur due to recovery of myocardial stunning and recuperation of hibernating myocardium. Predictors of recovery in LVEF following STEMI are not well established. We sought to investigate predictors of LVEF recovery in patients with left ventricular systolic dysfunction in the acute setting and assess the prognostic implications of change in LVEF. Methods Consecutive patients with STEMI undergoing primary PCI from a large volume single centre who had LVEF assessment prior to hospital discharge (acute LVEF) and during follow-up (follow-up LVEF) by echocardiogram were enrolled. Patients with preserved acute LVEF (>50%) were excluded from the analysis. LVEF recovery was calculated: EF Recovery = Follow-up LVEF – Acute LVEF. Clinical endpoint was defined as a composite of death, re-admission with heart failure, sustained ventricular arrhythmia or implantable cardioverter defibrillator (ICD) over three years follow-up. Results 313 patients with STEMI had both acute and follow-up LVEF assessments of which 103 patients with acute LVEF >50% were excluded. 210 patients with acute LVEF ≤50% were included in the analysis. Mean age was 64±13 years and 76% were male. Anterior STEMI occurred in 51% of cases and 17% were diabetic. There was marked heterogeneity in LVEF recovery with 39% of patients demonstrating no EF recovery (figure 1). Age, hypertension and acute LVEF predicted LVEF recovery in unadjusted model, nonetheless, only acute LVEF was an independent predictor after adjustment for other risk factors (table 1). For every 5% increase in acute LVEF there was 45% less likelihood of any LVEF recovery, plausibly reflecting a stunning phenomenon. In those individuals who demonstrated LVEF recovery, only acute LVEF was a predictor of the magnitude of LVEF recovery. For every 5% increase in acute LVEF, there was more than 2% reduction in LVEF recovery (table 2). Importantly, LVEF recovery was a predictor of clinical outcomes. With every 5% increase in LVEF recovery there was a 16% reduction in the likelihood of sustaining an event (Hazard ratio 0.84, CI 0.74 – 0.95, pConclusion Acute LVEF is an independent predictor for recovery of left ventricular systolic function. LVEF recovery is a good measurement to predict patients who are less likely to have adverse clinical outcomes over long term follow-up.
49 Predictors and prognostic role of left ventricular ejection fraction recovery after st elevation myocardial infarction
Introduction Left ventricular ejection fraction (LVEF) is an important predictor of morbidity and mortality after ST elevation myocardial infarction (STEMI). In patients with left ventricular systolic dysfunction early after STEMI adverse ventricular remodelling can lead to a sustained reduction in LVEF, however, in some cases improvement may occur due to recovery of myocardial stunning and recuperation of hibernating myocardium. Predictors of recovery in LVEF following STEMI are not well established. We sought to investigate predictors of LVEF recovery in patients with left ventricular systolic dysfunction in the acute setting and assess the prognostic implications of change in LVEF. Methods Consecutive patients with STEMI undergoing primary PCI from a large volume single centre who had LVEF assessment prior to hospital discharge (acute LVEF) and during follow-up (follow-up LVEF) by echocardiogram were enrolled. Patients with preserved acute LVEF (>50%) were excluded from the analysis. LVEF recovery was calculated: EF Recovery = Follow-up LVEF – Acute LVEF. Clinical endpoint was defined as a composite of death, re-admission with heart failure, sustained ventricular arrhythmia or implantable cardioverter defibrillator (ICD) over three years follow-up. Results 313 patients with STEMI had both acute and follow-up LVEF assessments of which 103 patients with acute LVEF >50% were excluded. 210 patients with acute LVEF ≤50% were included in the analysis. Mean age was 64±13 years and 76% were male. Anterior STEMI occurred in 51% of cases and 17% were diabetic. There was marked heterogeneity in LVEF recovery with 39% of patients demonstrating no EF recovery (figure 1). Age, hypertension and acute LVEF predicted LVEF recovery in unadjusted model, nonetheless, only acute LVEF was an independent predictor after adjustment for other risk factors (table 1). For every 5% increase in acute LVEF there was 45% less likelihood of any LVEF recovery, plausibly reflecting a stunning phenomenon. In those individuals who demonstrated LVEF recovery, only acute LVEF was a predictor of the magnitude of LVEF recovery. For every 5% increase in acute LVEF, there was more than 2% reduction in LVEF recovery (table 2). Importantly, LVEF recovery was a predictor of clinical outcomes. With every 5% increase in LVEF recovery there was a 16% reduction in the likelihood of sustaining an event (Hazard ratio 0.84, CI 0.74 – 0.95, pConclusion Acute LVEF is an independent predictor for recovery of left ventricular systolic function. LVEF recovery is a good measurement to predict patients who are less likely to have adverse clinical outcomes over long term follow-up.
- Open Access
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 5 (4) , 588-594
Apoptosis block as a barrier to effective therapy in non small cell lung cancer
Apoptosis block as a barrier to effective therapy in non small cell lung cancer
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 5 (4) , 588-594
Open AccessApoptosis block as a barrier to effective therapy in non small cell lung cancer
Apoptosis block as a barrier to effective therapy in non small cell lung cancer
- 1 July 2007
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 84 (1) , 276-278
Traumatic Left Anterior Descending Artery–to–Pulmonary Artery Fistula With Delayed Pericardial Tamponade
- 1 July 2007
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 84 (1) , 276-278
Traumatic Left Anterior Descending Artery–to–Pulmonary Artery Fistula With Delayed Pericardial Tamponade
- Open Access
- 24 May 2007
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 2 (1) , 24
Concomitant mitral valve surgery with aortic valve replacement: a 21-year experience with a single mechanical prosthesis
Long-term survival for combined aortic and mitral valve replacement appears to be determined by the mitral valve prosthesis from our previous studies. This 21-year retrospective study assess long-term outcome and durability of aortic valve replacement (AVR) with either concomitant mitral valve replacement (MVR) or mitral valve repair (MVrep). We consider only a single mechanical prosthesis.
- 24 May 2007
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 2 (1) , 24
Open AccessConcomitant mitral valve surgery with aortic valve replacement: a 21-year experience with a single mechanical prosthesis
Long-term survival for combined aortic and mitral valve replacement appears to be determined by the mitral valve prosthesis from our previous studies. This 21-year retrospective study assess long-term outcome and durability of aortic valve replacement (AVR) with either concomitant mitral valve replacement (MVR) or mitral valve repair (MVrep). We consider only a single mechanical prosthesis.
- 1 July 2006
- Published by Elsevier in Lung Cancer
- Vol. 53 (1) , 97-101
Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer
- 1 July 2006
- Published by Elsevier in Lung Cancer
- Vol. 53 (1) , 97-101
Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer
- Open Access
- 7 February 2006
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 5 (3) , 327-330
Impact of coronary artery bypass grafting on survival after aortic valve replacement
Treatment of coronary artery disease by coronary artery bypass grafting (CABG) concurrently with aortic valve replacement (AVR) improves outcome but survival compared to isolated AVR remains uncertain, as does the role of the left internal mammary artery (LIMA) graft to the left anterior descending (LAD) artery. All 799 patients undergoing elective primary AVR, using the St. Jude Medical® mechanical prosthesis, with or without CABG, between March 1986 and May 2000, were reviewed with 100% follow-up. Operative mortality was 1.6% in 574 patients undergoing isolated AVR, 2.6% in 78 patients undergoing combined AVR and CABG with LIMA to LAD grafting (LIMA-AVR), 6.25% in 64 patients receiving vein grafts only to circumflex or right coronary artery territories (Non-LAD VG-AVR) and 2.4% in 83 patients receiving vein grafts to vessels including the LAD (LAD VG-AVR). Cox regression analysis showed improved survival after AVR compared to LAD VG-AVR (P=0.008), but with no significant difference to survival after LIMA-AVR (P=0.18) and Non-LAD VG-AVR (P=0.08). Multivariable regression analysis identified advanced age (PPP=0.02), number of grafts performed during surgery (P=0.04), non-congenital valvular pathology (P=0.001) and regurgitant valve disease (P=0.008) as independent predictors of reduced survival. LIMA-LAD grafting was not a significant variable in the multivariable model.
- 7 February 2006
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 5 (3) , 327-330
Open AccessImpact of coronary artery bypass grafting on survival after aortic valve replacement
Treatment of coronary artery disease by coronary artery bypass grafting (CABG) concurrently with aortic valve replacement (AVR) improves outcome but survival compared to isolated AVR remains uncertain, as does the role of the left internal mammary artery (LIMA) graft to the left anterior descending (LAD) artery. All 799 patients undergoing elective primary AVR, using the St. Jude Medical® mechanical prosthesis, with or without CABG, between March 1986 and May 2000, were reviewed with 100% follow-up. Operative mortality was 1.6% in 574 patients undergoing isolated AVR, 2.6% in 78 patients undergoing combined AVR and CABG with LIMA to LAD grafting (LIMA-AVR), 6.25% in 64 patients receiving vein grafts only to circumflex or right coronary artery territories (Non-LAD VG-AVR) and 2.4% in 83 patients receiving vein grafts to vessels including the LAD (LAD VG-AVR). Cox regression analysis showed improved survival after AVR compared to LAD VG-AVR (P=0.008), but with no significant difference to survival after LIMA-AVR (P=0.18) and Non-LAD VG-AVR (P=0.08). Multivariable regression analysis identified advanced age (PPP=0.02), number of grafts performed during surgery (P=0.04), non-congenital valvular pathology (P=0.001) and regurgitant valve disease (P=0.008) as independent predictors of reduced survival. LIMA-LAD grafting was not a significant variable in the multivariable model.